Additionally, ACAT1 was recently associated as a causal modifier variant explaining strain differences in mouse atherosclerosis pathology (218); although a cardiovascular benefit of ACAT inhibition has not been demonstrated in human ACAT inhibitor trials (219). Here, CES1 is linked to atherosclerosis.